Current research in translational medicine
Sustained remission in relapsed/refractory diffuse large B cell lymphoma following Glofitamab discontinuation due to JC virus reactivation: balancing efficacy and infectious risk.
Massimiliano Marinoni, Lucrezia De Marchi, Federico Meconi, Alice Di Rocco, Luca Franceschini, Marco Iannetta, Manuela Rizzo, Massimiliano Postorino, Adriano Venditti, Fabiana Esposito
Published: 202510.1016/j.retram.2025.103549
Abstract
BACKGROUND: The therapeutic landscape for relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) is expanding, with bispecific antibodies emerging as key treatment strategies. These drugs have demonstrated high efficacy in this setting of pati…
Preview only. Read the full abstract at the source